Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives (original) (raw)
A review of monoclonal antibody therapies in lymphoma
Yveline Chew
Critical Reviews in Oncology/Hematology, 2016
View PDFchevron_right
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
G. Dastoli
Critical Reviews in Oncology/Hematology, 2001
View PDFchevron_right
Novel CD20 monoclonal antibodies for lymphoma therapy
Nikhil Mukhi
Journal of Hematology & Oncology, 2012
View PDFchevron_right
Novel Strategies to Improve Rituximab Efficacy in Non-Hodgkin's Lymphomas
Peertechz Journals
View PDFchevron_right
Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations
maxine gossell-williams
The West Indian medical journal, 2014
View PDFchevron_right
Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
Julia Rincon
Cancer Treatment Reviews, 2015
View PDFchevron_right
[Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]
Angel Yepez
Gan to kagaku ryoho. Cancer & chemotherapy, 2002
View PDFchevron_right
Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma
Franck Morschhauser
Current Oncology Reports, 2011
View PDFchevron_right
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy
Joke Baars
Leukemia, 2003
View PDFchevron_right
Monoclonal antibody therapy for classical Hodgkin lymphoma
Jan Walewski
Clinical Investigation, 2013
View PDFchevron_right
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma
Maria Jesús Blanco
View PDFchevron_right
Highlights From: 43rd Annual Meeting of the American Society of Hematology December 7–11, 2001 Orlando, Florida: First International Congress on Monoclonal Antibodies in Cancer August 30-September 2, 2001 Banff, Alberta, Canada
Amy Dorazio
Clinical Lymphoma, 2001
View PDFchevron_right
Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
Ruben Niesvizky
Journal of Clinical Oncology, 2005
View PDFchevron_right
Monoclonal antibody therapy of cancer
Grégory ADAMS
Nature Biotechnology, 2005
View PDFchevron_right
Newer monoclonal antibodies for hematological malignancies
Jorge Gonzales Castillo
Experimental Hematology, 2008
View PDFchevron_right
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
Maulida Ilhamna
Scientific Reports, 2021
View PDFchevron_right
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Christoph Driessen
Blood, 2003
View PDFchevron_right
Rituximab in Hodgkin lymphoma: Is the target always a hit
monika saini
Cancer Treatment Reviews, 2011
View PDFchevron_right
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Srikanth Ambati
Blood
View PDFchevron_right
Rituximab: A Hope for Lymphoma Patients
sciepub.com SciEP
View PDFchevron_right
Monoclonal Antibody Therapy for Cancer
Grégory ADAMS
Annual Review of Medicine, 2003
View PDFchevron_right
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Jérôme Galon, Alexander Eggermont
Oncoimmunology, 2014
View PDFchevron_right
Monoclonal antibody: a cell specific immunotherapy to treat cancer
Fahim Islam
International Journal of Basic & Clinical Pharmacology
View PDFchevron_right
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
Simon Durrant
Journal of Clinical Oncology, 2013
View PDFchevron_right
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
Patrick Glassman
Cancer biology & medicine, 2014
View PDFchevron_right
Novel and Engineered Anti–B-Cell Monoclonal Antibodies for Non-Hodgkin’s Lymphoma
Ruben Niesvizky
Seminars in Hematology, 2008
View PDFchevron_right
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
Owen O'Connor
British journal of haematology, 2017
View PDFchevron_right